ShangPharma Innovation

Rila Therapeutics is a biotherapeutics company dedicated to developing innovative treatments for chronic fibrotic diseases, with a particular focus on renal fibrosis. The company's lead program centers on a first-in-class small molecule allosteric inhibitor targeting HIPK2, which aims to address critical unmet medical needs in the treatment of kidney fibrosis. By providing a safe and effective anti-fibrotic therapy, Rila Therapeutics seeks to significantly improve the quality of life for patients affected by this condition.

Founded in 2016, Pykus Therapeutics develops a dissolvable intraocular surgical device designed to enhance retinal surgery by reducing patient discomfort. The company's core innovation is a polymer-based hydrogel that replaces the use of intraocular gas during such procedures, eliminating the need for patients to maintain face-down positioning and facilitating quicker recovery.

Blue Oak Pharmaceuticals, Inc. is a pharmaceutical company focused on developing innovative drugs for brain disorders. Founded in 2016 and based in Concord, Massachusetts, the company employs a unique drug discovery paradigm that integrates custom-designed chemotypes with advanced technologies in behavioral profiling, synthetic chemistry, and brain imaging. Blue Oak's approach emphasizes in vivo phenotypic assays and systems-level neurobiology to identify first-in-class clinical candidates. The company aims to advance these candidates through early-phase proof-of-concept studies, utilizing translational medicine biomarkers to assess brain circuit activity. The team at Blue Oak comprises experts in neurobiology, medicinal chemistry, and informatics, fostering a collaborative environment that combines established partnerships with cutting-edge research methodologies.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Valitor, Inc. is a biotechnology company based in Berkeley, California, founded in 2010. The company specializes in the development of advanced, protein-based drugs and has established innovative methods for modifying therapeutic proteins. This technology enables enhanced control over pharmacokinetics, target specificity, and bioactivity, thus improving the pharmacological properties of existing and emerging protein drugs. Valitor's research and development efforts are focused on three key areas: dermatology, ophthalmology, and orthopedics, where they are advancing novel drug products designed to address unmet medical needs in these fields.

Skyhawk Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small molecule therapeutics that aim to correct RNA expression. The company's proprietary technology facilitates the rational design of these small molecules to target specific binding pocket regions on RNA, employing both sequence and structural specificity at critical moments during the RNA splicing process. This innovative approach allows for the targeting of diseases associated with RNA mis-splicing, particularly those characterized by exon skipping. Skyhawk Therapeutics is committed to developing treatments for various conditions, including cancer, neurological diseases, and rare disorders. Founded in 2015 and headquartered in Waltham, Massachusetts, the company has evolved from its initial identity as Rare Genetix, Inc., adopting its current name in May 2018.

Evrys Bio, LLC is a pharmaceutical company focused on developing innovative antiviral drugs that target sirtuins, proteins that play a crucial role in enhancing the body's intrinsic immune response. The company is engaged in creating broad-spectrum antiviral treatments for various infections, including respiratory syncytial virus, herpes, polyomavirus, and hepatitis viruses. Notably, Evrys Bio aims to offer a pill for treating diverse infections and a brain-penetrant antiviral for conditions like viral encephalitis. By leveraging breakthroughs from Princeton University, Evrys Bio seeks to address the challenge of acquired drug resistance and provide unique treatment options that enhance patient outcomes holistically, rather than targeting specific viruses. Established in 2012 and based in Doylestown, Pennsylvania, the company was formerly known as FORGE Life Science, LLC before rebranding in 2019.

Tilos Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative antibody therapeutics aimed at treating cancer, fibrosis, and related disorders. Founded in 2016 and based in Cambridge, Massachusetts, the company specializes in antibodies that target the Latency Associated Peptide of TGF beta, which plays a crucial role in regulating immune responses. Tilos Therapeutics is particularly focused on the modulation of regulatory T cells and effector cell regulation, leveraging the immune system to create effective therapies. By enhancing treatment options, Tilos aims to enable patients to begin their therapies more swiftly, ultimately leading to improved medical outcomes. As of mid-2019, Tilos operates as a subsidiary of Merck & Co., Inc.

Rodin Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through epigenetic modulation. Founded in 2013, the company leverages insights into key epigenetic regulators of central nervous system (CNS) function to create innovative treatments. Rodin's approach involves harnessing the power of epigenetic regulation, particularly through the modulation of HDAC complexes, to restore synaptic function and enhance neuronal health in patients suffering from degenerative brain diseases. The company is supported by a team experienced in CNS drug development and has access to advanced structural biology capabilities. Rodin Therapeutics operates as a subsidiary of Alkermes Inc.

Quartet Medicine is a private biotechnology company based in Cambridge, Massachusetts, focused on developing novel treatments for chronic pain and inflammation. Founded in 2013 by scientists at Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, the company aims to restore tetrahydrobiopterin (BH4) homeostasis in neuronal and inflammatory cells. This approach is based on insights from human genetics and preclinical target validation data, which highlight BH4's role as a critical mediator of peripheral nerve dysfunction and immune cell regulation. Quartet Medicine's efforts are directed towards creating non-opioid medications that safely address chronic pain and inflammation by targeting BH4 levels at the nexus of the peripheral nervous system.